On-Demand Pharmacology CE
77 Results
In accordance with the Medication Access and Training Expansion (MATE) Act, beginning June 7, 2023, all providers who are registered with the DEA are required to complete 8 hours of training on the treatment and management of patients with opioid and other substance use disorders. This bundle fully satisfies this one-time requirement.
Total Credits: 9.00 contact hours; 8.5 are pharmacology
Expiration Date: June 30, 2024$225
-
Register
- User - $225
- More Information
-
Register
Merck Grant Funded Program
The overall goal of this program is to address the barriers in vaccination uptake and integration.
Credits: 1.0 contact hours; 1.0 are Pharmacology
FREE
-
Register
- User - Free!
- More Information
-
Register
Adolescent substance use has followed familiar trends for several decades with alcohol, nicotine, and cannabis leading other drugs in popularity. After several years of declining nicotine use, primarily via combustible cigarettes, recent data suggests a resurgence of nicotine use, primarily via e-cigarettes as well as a marked increase in cannabis use, likely corresponding with legalization efforts. Additionally, there has been an increase in hallucinogen use and the dangers of opioid use have heightened due to the rise of illicit fentanyl being brought in from outside the United States. This lecture will review the most recent Monitoring the Future study and discuss implications of adolescent substance use trends on healthcare providers.
Credits: 1.50 Contact Hours; 1.50 are Pharmacology
Expiration Date: December 31st, 2024$40
-
Register
- User - $40
- More Information
-
Register
Influenza and COVID-19 are both respiratory illnesses that can cause serious complications, especially in high-risk populations. Nurse practitioners play a key role in the diagnosis and treatment of influenza and COVID-19 infections. This presentation will evaluate the different types of antiviral medications and their pharmacologic features. Patient populations who are most likely to benefit from antiviral therapy will be reviewed. This presentation will examine the most up to date evidence related to efficacy and safety of antivirals for influenza and COVID-19, and provide an approach to the appropriate use of these medications in clinical practice.
Credits: 1.50 Contact Hours; 1.50 are Pharmacology
$40
-
Register
- User - $40
- More Information
-
Register
In 2019, the Infectious Disease Society of America and American Thoracic Society published updated recommendations for managing patients with community-acquired pneumonia (CAP) generating new considerations for inpatient and outpatient practitioners. This presentation will assess emerging literature influencing the optimal pharmacologic management of CAP such as, changing etiologic trends, patient-specific factors, outcomes evidence, and risk factors for adverse drug reactions.
Credits: 1.50 Contact Hours; 1.50 are Pharmacology
$40
-
Register
- User - $40
- More Information
-
Register
This session will provide the nurse practitioner with information regarding common pathogens implicated in AECB and community acquired pneumonia in the patient with underlying co-morbidities such as asthma, COPD and alcohol abuse. Current recommendations regarding antimicrobial treatment options will be reviewed in detail. National recommendations for obtaining chest x-ray and sputum for gram staining will also be discussed.
Credits: 1.50 Contact Hours; 1.50 are Pharmacology
Expiration Date: December 31st, 2024$45
-
Register
- User - $45
- More Information
-
Register
Updated diagnostic criteria and disease models for anxiety disorders are reviewed. Neurobiological and epigenetic mechanisms that underlie anxiety symptoms are presented as the basis for therapeutic interventions. Specific attention is given to the formulation of rational, genomically-informed pharmacologic treatment approaches for anxiety disorders. Practical applications for nurse practitioners are presented.
Credits: 1.50 Contact Hours; 1.50 are Pharmacology
$40
-
Register
- User - $40
- More Information
-
Register
Atrial fibrillation (AF) remains the most common heart arrhythmia in the general population and is associated with significant morbidity and mortality. Appropriate identification and treatment are critical to prevent potential devastating sort-and long-term outcomes. Practitioners in all areas of practice will encounter patients with various stages of AF, and therefore must be able to identify, classify and treat this common arrhythmia. This session will focus on the classification of AF, identification and various treatment and preventative options.
Credits: 1.50 contact hours; 0.75 are pharmacology
$40
-
Register
- User - $40
- More Information
-
Register
This presentation will discuss common laboratory studies utilizing a case-based method. Then review decision-making strategies including the selection of the most appropriate tests for the clinical presentation, based on the current evidence. Lastly, explore the interpretation of the potential findings and develop the best treatment plans as well as any necessary follow-up that may be needed based on the findings.
Credits: 1.00 contact hours; 0.25 are pharmacology
Expiration Date: December 31st, 2024$27.50
-
Register
- User - $27.50
- More Information
-
Register
Pfizer Grant Funded Program
The overall goal of this program is to deliver targeted educational interventions to (1) improve health outcomes among outpatients with COVID-19 by building skills, knowledge, and competencies of providers that serve them, and (2) address provider knowledge gaps related to Drug-to-Drug Interactions (DDIs) in COVID-19 treatment.
Credits: 1.0 contact hours; 1.0 are pharmacology
Expiration Date: June 30, 2024FREE
-
Register
- User - Free!
- More Information
-
Register
